|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/23/18 Advaxis, Inc. S-3 6:2.3M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: S-3 Registration Statement for Securities Offered HTML 322K
Pursuant to a Transaction
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 461K
3: EX-4.3 Instrument Defining the Rights of Security Holders HTML 486K
4: EX-5.1 Opinion re: Legality HTML 17K
6: EX-23.1 Consent of Experts or Counsel HTML 7K
5: EX-12.1 Statement re: Computation of Ratios HTML 20K
Exhibit 12.1
Advaxis, Inc.
Computation of Ratio of Earnings to Fixed Charges
(in millions)
| Years Ended October 31, | Nine Months Ended | |||||||||||||||||||||||
| 2017 | 2016 | 2015 | 2014 | 2013 | 2018 | |||||||||||||||||||
| Fixed Charges: | ||||||||||||||||||||||||
| Interest expense | $ | — | $ | — | $ | — | $ | — | $ | 1.0 | $ | — | ||||||||||||
| Interest expense on portion of rent expense representative of interest | — | — | — | — | — | — | ||||||||||||||||||
| Total Fixed Charges | $ | — | $ | — | $ | — | $ | — | $ | 1.0 | $ | — | ||||||||||||
| Earnings (loss): | ||||||||||||||||||||||||
| Pre-tax income (loss) from continuing operations | $ | (97.8 | ) | $ | (76.1 | ) | $ | (48.6 | ) | $ | (18.9 | ) | $ | (18.9 | ) | $ | (47.8 | ) | ||||||
| Fixed charges per above | — | — | — | — | 1.0 | — | ||||||||||||||||||
| Total earnings (loss) | $ | (97.8 | ) | $ | (76.1 | ) | $ | (48.6 | ) | $ | (18.9 | ) | $ | (17.9 | ) | $ | (47.8 | ) | ||||||
| Ratio of earnings to fixed charges | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||||||||||
| Deficiency of earnings available to cover fixed charges | $ | (97.8 | ) | $ | (76.1 | ) | $ | (48.6 | ) | $ | (18.9 | ) | $ | (17.9 | ) | $ | (47.8 | ) | ||||||
| Preferred share dividend requirements | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||
| Total combined fixed charges and preferred share dividends | $ | — | $ | — | $ | — | $ | — | $ | 1.0 | $ | — | ||||||||||||
| Ratios of earnings to combined fixed charges and preferred share dividends | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||||||||||
| Deficiency of earnings available to cover fixed charges and preferred share dividend requirements | $ | (97.8 | ) | (76.1 | ) | $ | (48.6 | ) | $ | (18.9 | ) | $ | (18.9 | ) | $ | (47.8 | ) | |||||||
C:
| This ‘S-3’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/23/18 | |||
| 7/31/17 | 10-Q, 4 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/28/18 SEC UPLOAD¶ 9/28/18 1:44K Ayala Pharmaceuticals, Inc. |